{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:09Z","timestamp":1787786169574,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2016.10.055","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T15:45:42Z","timestamp":1488555942000},"page":"1764-1769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies"],"prefix":"10.1016","volume":"35","author":[{"given":"Janie","family":"Parrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly A.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco F.","family":"Pagnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan S.F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.055_b0005","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/jmv.10364","article-title":"Varicella in Americans from NHANES III: implications for control through routine immunization","volume":"70","author":"Kilgore","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2016.10.055_b0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.055_b0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.10.055_b0020","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.06.012","article-title":"Herpes zoster in immunocompromised patients: incidence, timing, and risk factors","volume":"118","author":"Wung","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2016.10.055_b0025","first-page":"976","article-title":"Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2016.10.055_b0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428199309067939","article-title":"Patient education for self-referral and on-demand treatment for herpes zoster in lymphoma patients","volume":"11","author":"Maung","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vaccine.2016.10.055_b0035","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1988.00380070065016","article-title":"Varicella-zoster infection in adult cancer patients","volume":"148","author":"Rusthoven","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2016.10.055_b0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/infdis\/153.5.840","article-title":"Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients","volume":"153","author":"Ljungman","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.055_b0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1056\/NEJM198601233140404","article-title":"Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine","volume":"314","author":"Shepp","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.055_b0050","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","article-title":"Infection with varicella-zoster virus after marrow transplantation","volume":"152","author":"Locksley","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.055_b0055","unstructured":"Zostavax (zoster vaccine, live) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006. Available at: <http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm132831.pdf> [accessed 05-Feb-2016]."},{"key":"10.1016\/j.vaccine.2016.10.055_b0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.055_b0065","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1086\/514077","article-title":"Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine","volume":"176","author":"Redman","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.055_b0070","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated Zoster Vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.055_b0075","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.10.055_b0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcv.2010.11.013","article-title":"Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment","volume":"50","author":"Mackay","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2016.10.055_b0085","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.055_b0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2016.10.055_b0095","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2016.10.055_b0100","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CDLI.8.5.871-879.2001","article-title":"Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus","volume":"8","author":"Smith","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2016.10.055_b0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2016.10.055_b0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The epidemiology of herpes zoster in patients with newly diagnosed cancer","volume":"22","author":"Habel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2016.10.055_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Veterans affairs cooperative studies program shingles prevention study investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T10:00:03Z","timestamp":1601719203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":23,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X16309902"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}